Entelos, Inc. (LSE:ENTL) is pleased to announce that Gregory T. Schiffman, MBA, CPA, has joined the Company’s Board of Directors. The appointment is effective as of February 12, and Mr. Schiffman will lead Entelos’ Audit Committee as chair.
Mr. Schiffman, 48, recently joined Seattle-based Dendreon Corporation (NASDAQ:DNDN) as Chief Financial Officer (CFO). Prior to that, he served as CFO and executive vice president at Affymetrix, Inc. (NASDAQ:AFFX), a position he held for five years. Earlier, Mr. Schiffman was vice president and controller for Applied Biosystems where he managed a 200-person global finance team spanning more than 20 countries. He has also held senior management positions at Hewlett Packard, serving for over 10 years in various domestic and international divisions, and IBM. Mr. Schiffman holds a Master's in Business Administration from the Kellogg Graduate School of Management at Northwestern University and a Bachelor of Science degree in accounting from DePaul University.
Mr. Schiffman also holds current directorships at Nanomix, Inc. and VNUS Medical Technologies, Inc. (NASDAQ:VNUS). Within the last five years, he also has held past directorships at Impac Medical Systems and Xenogen Corporation.
"We are pleased to welcome Greg Schiffman to the Entelos Board of Directors," said James Karis, president and CEO of Entelos. "His depth and breadth of experience across the industry will greatly benefit Entelos as we enter our next phase of growth."
Mr. Schiffman will become the chair of the Entelos Audit Committee. Simon Best, the current chair of the Audit Committee, will step down as chair but will remain on the committee. There is no further information required to be disclosed pursuant to Schedule 2(g) of the AIM rules.
About Entelos
Entelos, Inc. (www.entelos.com) builds predictive in silico disease models and uses “virtual patients” to revolutionize the way medicines are discovered, developed, and utilized. The Company’s predictive computer models, known as PhysioLab® systems, are used to validate novel drug targets, select and develop compounds, assess safety, optimize clinical trials and combination therapies, reprofile drugs, evaluate in-licensing candidates, and better position existing products in competitive markets. In addition to internal programs, Entelos partners with global pharmaceutical and biotechnology companies and currently provides scientific expertise and models in such areas as cardiovascular disease, asthma, obesity, diabetes and rheumatoid arthritis, and complex physiological processes such as hematopoiesis (anemia), cholesterol metabolism, and skin sensitization.
Entelos is a registered trademark of Entelos, Inc. PhysioLab is a trademark and service mark of Entelos, Inc.
All other trademarks are the property of their registered owners.
